Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Leukemia

Recurrence

Neoplasms by Histologic Type

Hematologic Diseases

Disease Attributes

The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.

Hem(A)+ Technology

Leonard S. Sender, MD

The objective of this protocol is to collect leukemia cell specimens from adults (18 years of age) diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse. These specimens, in conjunction with a de-identified data set, will be utilized prospectively to determine potential chemotherapy resistance in this patient population.

The specific aims of this study are as follows:

To collect peripheral blood specimens from patients diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse To evaluate the leukemia cells in the blood specimens for chemotherapy resistance utilizing the Hem(A)+ technology

To develop a body of evidence from acute leukemia patients that demonstrates the applicability of the Hem(A)+ assay to determine the following:

Predict responders and non-responders to common chemotherapeutic agents Track treatment results and comparison to prediction results from the assay Identify optimal chemotherapy doses for each patient Identify the most efficacious pharmaceutical agent combinations

Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients

University of California, Irvine

Leonard Sender, M.D.

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Ovarian Cancer

Ovarian Epithelial Cancer

25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.

Treatment continues until progression or unacceptable toxicity.

Cabazitaxel

Karina D Steffensen

Many ovarian cancer patients have been offered different standard cytostatics and gradually develop chemo-resistance. However, a considerable fraction of these patients are still in good general health and have a strong wish for further treatment.

Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both tumors it has shown effect in patients refractory to docetaxel. Therefore, it could be anticipated that cabazitaxel may also have an effect in chemo-resistant ovarian cancer.

The aim of the study is to investigate whether cabazitaxel could be a reasonable treatment option in patients with chemo-resistant and refractory ovarian cancer with regard to effect and toxicity.

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase II Trial

Vejle Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients	NCT00631059	Leukemia	Hem(A)+ Technol...	18 Years -	University of California, Irvine
Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients	NCT00631059	Leukemia	Hem(A)+ Technol...	18 Years -	University of California, Irvine
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.	NCT02560337	Ovarian Cancer	Cabazitaxel	18 Years -	Vejle Hospital

Spots Global Cancer Trial Database for chemotherapy resistance